SS-31

SS-31, also known as elamipretide and formerly MTP-131, is a synthetic tetrapeptide with an alternating aromatic-cationic structure. That structure is functional rather than incidental: it causes the peptide to concentrate selectively at the inner mitochondrial membrane, reaching local concentrations far above those elsewhere in the cell, without requiring a membrane potential to accumulate.

Once there it binds cardiolipin, the signature phospholipid of the inner mitochondrial membrane. Cardiolipin organises the respiratory supercomplexes of the electron transport chain and maintains cristae architecture, and its peroxidation is one of the best-characterised molecular features of mitochondrial dysfunction in ageing and disease.

The preclinical literature follows from that mechanism and is substantial. Studies report improved ATP production efficiency, reduced reactive oxygen species generation, preserved cristae structure, and functional protection in models of ischemia-reperfusion injury, heart failure, acute kidney injury and age-related skeletal muscle decline. The mechanism is unusually well specified for a compound in this catalogue.

SS-31 has by far the most developed clinical programme of anything on the longevity shelf. Stealth BioTherapeutics advanced elamipretide into multiple controlled human trials, and the results are genuinely mixed in a way that is worth stating accurately.

In primary mitochondrial myopathy, the MMPOWER-3 phase 3 trial did not meet its primary endpoint. In Barth syndrome, a rare genetic disorder involving defective cardiolipin remodelling — the mechanism SS-31 directly targets — the TAZPOWER trial and its open-label extension reported functional improvements over longer treatment periods, and elamipretide has been pursued for that indication through regulatory review. Trials have also been conducted in dry age-related macular degeneration and in heart failure.

Elamipretide does not hold general marketing approval. What this record provides that almost nothing else here does is real controlled human safety and efficacy data, including negative results — which are as informative as positive ones and are routinely omitted from promotional material.

The claim that SS-31 targets mitochondria specifically is true and unusually well substantiated. The cardiolipin-binding mechanism is characterised at a level of molecular detail rare in this field.

The claim that it is a proven mitochondrial repair agent overstates the clinical record. The phase 3 failure in primary mitochondrial myopathy is a real result. It indicates that a compelling mechanism and strong preclinical data did not translate into a clinical benefit for that population on that endpoint — the ordinary and instructive outcome of drug development.

The Barth syndrome results are more encouraging and also more specific: that condition involves a defect in cardiolipin remodelling, so it is the population where a cardiolipin-targeting compound would be most expected to work. Generalising from a rare disease with a directly matched mechanism to healthy ageing is a substantial and unsupported leap.

Claims about anti-ageing effects in healthy people have no supporting human trial data.

Against MOTS-c, both target mitochondria and do so completely differently. SS-31 physically localises to the inner membrane and stabilises cardiolipin, a structural intervention. MOTS-c is an endogenous signalling peptide acting through AMPK and nuclear gene expression. SS-31 also has controlled human trial data, including negative results; MOTS-c has none.

Against NAD+ and its precursors, the distinction is substrate versus structure. NAD+ approaches supply or spare the redox cofactor that mitochondrial metabolism consumes. SS-31 targets the membrane platform on which that metabolism is organised. In principle complementary; neither established in healthy human ageing.

Against the antioxidant framing often applied to this shelf, SS-31 is not a conventional radical scavenger. It reduces reactive oxygen species generation by improving electron transport chain efficiency, which is a different and more targeted mechanism than mopping up radicals after the fact.

SS-31 has a real clinical safety dataset, which is unusual here and worth using. Reported adverse effects in trials were predominantly injection site reactions, which were common enough to be a practical limitation of the subcutaneous formulation. Gastrointestinal effects and headache were also reported.

The more important caution concerns interpretation rather than toxicity. A failed phase 3 endpoint is a signal that the compound did not do what its mechanism predicted in that population. Using it outside any studied indication means operating well beyond where the evidence, positive or negative, extends.

Mitochondrial function is not uniformly desirable to maximise. Reactive oxygen species have physiological signalling roles, including in exercise adaptation and in the process by which damaged cells are eliminated. Chronic pharmacological suppression of mitochondrial ROS has consequences that have not been characterised in healthy humans.

Long-term safety beyond trial durations, and safety in populations without mitochondrial disease, remain unestablished.

SS-31 is a tetrapeptide, short and comparatively stable, and it dissolves readily. Reconstitute with bacteriostatic water directed against the vial wall and swirl gently rather than shaking.

Store reconstituted solutions at 2–8 °C protected from light and observe the working window given on this page. Keep unopened lyophilized powder frozen for long-term storage, and aliquot before freezing if the vial will be drawn on more than once.